Evaluation of Allergy to Tacrolimus in Kidney Transplant Candidates and Recipients with a History of Macrolide Antibiotic Allergy
J. Trofe-Clark,1,2 M. Doshi,3 O. Fadugba,4 M. Lim.2
1Pharmacy Services, Hospital of Univ. of Pennsylvania, Philadelphia, PA
2Renal Division, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA
3Temple Univ. School of Pharmacy, Philadelphia, PA
4Pulmonary Allergy Critical Care Division, Perelman School of Medicine, Univ. of Pennsylvania, Philadelphia, PA.
Meeting: 2018 American Transplant Congress
Abstract number: A180
Keywords: FK506, Immunosuppression, Kidney transplantation, Safety
Session Information
Session Name: Poster Session A: Kidney Transplant Goes Viral
Session Type: Poster Session
Date: Saturday, June 2, 2018
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall 4EF
Background: Tacrolimus (TAC) is considered a drug of choice for maintenance immunosuppression among kidney transplant (KTX) recipients. Because of structural resemblances between macrolide antibiotics (azithromycin, clarithromycin or erythromycin) and TAC (a non-antibiotic macrolide), concern has been raised over TAC use in KTX recipients with a known macrolide antibiotic allergy. To date, only one published report describes a bone marrow transplant recipient with a clarithromycin allergy (rash), who also experienced rash and diffuse, generalized erythema with intravenous TAC. The aim of this study was to determine if KTX candidates and recipients with a known macrolide antibiotic allergic reaction also display an allergic reaction to TAC. Methods: We conducted an IRB-approved, single-center, retrospective review of adult patients who were evaluated for KTX at our center between 01/01/01-10/15/17, and had a reported allergy to any macrolide antibiotics. Only patients who subsequently underwent a TAC allergy evaluation and/or subsequently received TAC after KTX were included for analysis. Data were collected through October 31, 2017. Allergies to macrolide antibiotics were defined as a likely IgE-mediated hypersensitivity reaction such as hives, rash, shortness of breath, face, throat or tongue-swelling, or anaphylaxis. Results: Seven patients met inclusion criteria. Three patients underwent TAC allergy testing via skin prick test followed by an oral graded dose challenge pre-KTX and were not found to have an allergy to TAC. One of the tested patients subsequently received a KTX and TAC therapy without complications. Four additional patients did not undergo allergy testing pre-KTX, but received TAC post-KTX without complications. Conclusion: Our results did not identify any cross-reactivity between allergies to a macrolide antibiotic and TAC. It is important to evaluate cross-reactivity between macrolide antibiotic allergies and TAC to ensure that KTX recipients can safely receive current standard of care immunosuppression.
CITATION INFORMATION: Trofe-Clark J., Doshi M., Fadugba O., Lim M. Evaluation of Allergy to Tacrolimus in Kidney Transplant Candidates and Recipients with a History of Macrolide Antibiotic Allergy Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Trofe-Clark J, Doshi M, Fadugba O, Lim M. Evaluation of Allergy to Tacrolimus in Kidney Transplant Candidates and Recipients with a History of Macrolide Antibiotic Allergy [abstract]. https://atcmeetingabstracts.com/abstract/evaluation-of-allergy-to-tacrolimus-in-kidney-transplant-candidates-and-recipients-with-a-history-of-macrolide-antibiotic-allergy/. Accessed November 25, 2024.« Back to 2018 American Transplant Congress